Bispecific and Trispecific Anti-Env Antibodies for Eliminating HIV Reservoir Cells

用于消除 HIV 储存细胞的双特异性和三特异性抗 Env 抗体

基本信息

  • 批准号:
    10224769
  • 负责人:
  • 金额:
    $ 71.39万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-07-10 至 2023-06-30
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT Antibodies constitute a powerful weapon to fight viral infections. They could neutralize the infectivity of virus particles as well as mediate killing of productively infected cells via mechanisms such as antibody-dependent cell-mediated cytotoxicity (ADCC). In the past five years, our group has utilized the advances made in the antibody engineering field, as well as the growing lists of broadly neutralization antibodies (bNAbs) identified by other investigators, to construct new bispecific antibodies that have exquisite antiviral breadth and potency for the purpose of HIV-1 prevention. Now, with this proposal, we wish to expand our antibody engineering effort to generate a collection of bispecific and trispecific antibodies that are optimized for killing of Env-expressing cells, and for important properties such as pharmacokinetics. Instead of screening for virus-neutralization activity as we have previously done, we will now engineer and screen a library of Env-targeting multi-specific antibodies for cell-binding and cell-killing activities in vitro. The best performing antibody constructs will then be evaluated systematically in vivo in a humanized mouse model for the effect on their cell-killing capacity, their ability to restrict or eliminate latent reservoir cells after activation, and their ability to prevent or limit the establishment of the HIV-1 latent reservoir. Along with our knowledge of HIV-1 bNAbs and antibody engineering, our deep understanding of viral dynamics and our prior experience studying the HIV-1 latent reservoir will be brought to bear on the design, conduct, and interpretation of experiments to evaluate and quantify the antiviral effects of our top antibody constructs in humanized mice. Our group has successfully engineered two bispecific antibodies with exquisite HIV-1-neutralizing activity, and we have since extended our know-how in antibody engineering to the construction of bispecific or trispecific antibodies that target Env for the purpose of facilitating the elimination of infected cells. In the end, we hope to offer to the field one or two multi-specific antibodies that could be applied toward the elimination of latent reservoir cells as one critical component of a multi-pronged approach to HIV-1 eradication.
项目摘要/摘要 抗体是对抗病毒感染的有力武器。它们可以中和病毒的传染性 颗粒以及通过抗体依赖等机制介导对受感染细胞的杀伤 细胞介导的细胞毒性(ADCC)。在过去的五年中,我们集团利用了在 抗体工程领域,以及越来越多的广谱中和抗体(BNAbs),由 其他研究人员,构建新的双特异性抗体,具有精致的抗病毒广度和效力 预防HIV-1的目的。现在,通过这项提议,我们希望将我们的抗体工程努力扩大到 产生一组双特异性和三特异性抗体,这些抗体是针对杀死Env表达而优化的 细胞,以及重要的性质,如药代动力学。而不是筛查病毒中和 正如我们之前所做的那样,我们现在将设计和筛选一个针对环境的多特定 体外细胞结合和细胞杀伤活性的抗体。性能最好的抗体构建体将 在人源化的小鼠模型中系统地评估其对细胞杀伤能力的影响, 它们在激活后限制或消除潜伏的储集层细胞的能力,以及它们防止或限制 HIV-1潜伏库的建立。随着我们对HIV-1bNAbs和抗体的了解 工程学,我们对病毒动力学的深刻理解和我们以前研究HIV-1潜伏期的经验 将使储集层对实验的设计、实施和解释产生影响,以评估和 量化我们的顶级抗体构建物在人源化小鼠中的抗病毒效果。 我们的团队已经成功地设计出两种具有精致的HIV-1中和活性的双特异性抗体,以及 自那以后,我们将我们在抗体工程方面的技术诀窍扩展到构建双特异性或三特异性 以Env为靶标的抗体,目的是促进清除受感染的细胞。最后,我们希望 向现场提供一到两种可用于消除潜伏的多特异性抗体 将储存细胞作为多管齐下根除艾滋病毒-1方法的一个关键组成部分。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID D HO其他文献

DAVID D HO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID D HO', 18)}}的其他基金

Multiplex Small Molecule Discovery to Identify Broad-Acting Viral Protease Inhibitors
多重小分子发现来鉴定广泛作用的病毒蛋白酶抑制剂
  • 批准号:
    10513925
  • 财政年份:
    2022
  • 资助金额:
    $ 71.39万
  • 项目类别:
Quantifying Effector Functions of Anti-HIV IgG1 Antibodies In Vivo.
体内量化抗 HIV IgG1 抗体的效应器功能。
  • 批准号:
    10078502
  • 财政年份:
    2019
  • 资助金额:
    $ 71.39万
  • 项目类别:
Quantifying Effector Functions of Anti-HIV IgG1 Antibodies In Vivo.
体内量化抗 HIV IgG1 抗体的效应器功能。
  • 批准号:
    10239076
  • 财政年份:
    2019
  • 资助金额:
    $ 71.39万
  • 项目类别:
Quantifying Effector Functions of Anti-HIV IgG1 Antibodies In Vivo.
体内量化抗 HIV IgG1 抗体的效应器功能。
  • 批准号:
    10866743
  • 财政年份:
    2019
  • 资助金额:
    $ 71.39万
  • 项目类别:
Quantifying Effector Functions of Anti-HIV IgG1 Antibodies In Vivo.
体内量化抗 HIV IgG1 抗体的效应器功能。
  • 批准号:
    10005113
  • 财政年份:
    2019
  • 资助金额:
    $ 71.39万
  • 项目类别:
Bispecific-Antibody-Drug Conjugates for Selective Targeting and Activation of the HIV Latent Reservoir
用于选择性靶向和激活 HIV 潜伏库的双特异性抗体药物偶联物
  • 批准号:
    10078006
  • 财政年份:
    2017
  • 资助金额:
    $ 71.39万
  • 项目类别:
Bispecific and Trispecific Anti-Env Antibodies for Eliminating HIV Reservoir Cells
用于消除 HIV 储存细胞的双特异性和三特异性抗 Env 抗体
  • 批准号:
    10083601
  • 财政年份:
    2017
  • 资助金额:
    $ 71.39万
  • 项目类别:
Bispecific-Antibody-Drug Conjugates for Selective Targeting and Activation of the HIV Latent Reservoir
用于选择性靶向和激活 HIV 潜伏库的双特异性抗体药物偶联物
  • 批准号:
    10222490
  • 财政年份:
    2017
  • 资助金额:
    $ 71.39万
  • 项目类别:
Combination Clostridium Difficile Toxin and Adhesin Vaccine
艰难梭菌毒素和粘附素联合疫苗
  • 批准号:
    8686731
  • 财政年份:
    2012
  • 资助金额:
    $ 71.39万
  • 项目类别:
Combination Clostridium Difficile Toxin and Adhesin Vaccine
艰难梭菌毒素和粘附素联合疫苗
  • 批准号:
    8290921
  • 财政年份:
    2012
  • 资助金额:
    $ 71.39万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 71.39万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 71.39万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 71.39万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 71.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 71.39万
  • 项目类别:
    Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 71.39万
  • 项目类别:
    Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
  • 批准号:
    10065645
  • 财政年份:
    2023
  • 资助金额:
    $ 71.39万
  • 项目类别:
    Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 71.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 71.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 71.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了